Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study

BACKGROUND: The Canadian Bleeding Disorders Registry (CBDR) captures data from 24 hemophilia treatment centers and patients directly. Nonacog beta pegol (N9‐GP) was approved in Canada in 2018. OBJECTIVES: To assess treatment outcomes following switching to N9‐GP in a real‐world setting. METHODS: CBD...

Descripción completa

Detalles Bibliográficos
Autores principales: Matino, Davide, Iorio, Alfonso, Keepanasseril, Arun, Germini, Federico, Caillaud, Alexandre, Carcao, Manuel, Hews‐Girard, Julia, Iserman, Emma, James, Paula, Lee, Adrienne, Phua, Chai W., Sun, Haowei (Linda), Teitel, Jerome, Poon, Man‐Chiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971162/
https://www.ncbi.nlm.nih.gov/pubmed/35386274
http://dx.doi.org/10.1002/rth2.12661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971162/
https://www.ncbi.nlm.nih.gov/pubmed/35386274
http://dx.doi.org/10.1002/rth2.12661

Ejemplares similares